VUNO Med®-DeepECG(TM) Designated as Breakthrough Device
Wednesday, November 10, 2021
SEOUL, South Korea, Nov. 2, 2021 /PRNewswire/ -- South Korean artificial intelligence (AI) developer, VUNO inc. announced that the Korean Ministry of Food and Drug Safety (KFDA) has designated the company's artificial intelligence-based electrocardiogram (ECG) analysis software VUNO Med®-DeepECG(TM) as the ministry's 16(th) Breakthrough Device. Using deep learning, the software analyzes ECG data to zero in on heart failure, myocardial infarction and arrhythmia.
Although healthcare authorities such as the U.S. Preventive Services Task Force have pointed out the limitations of ECG tests on identifying cardiovascular diseases, the VUNO Med®-DeepECG(TM) can pinpoint even minute differences in ECG data that escape visual analysis by learning the ECG data of patients suffering from heart failure, myocardial infarction and other major heart-related disorders. Through this learning process, the device provides additional information on heart failure undetected in previous ECGs to identify a myocardial infarction even if no major deflections in the ECG wave patterns can be seen.
VUNO Med®-DeepECG(TM), once implemented in clinical practice, could help reduce mortality rates from major heart diseases and improve patient quality of life through early detection of symptomless patients through ECG testing and timely treatment.
VUNO Chairman Lee Yeha said, "VUNO will continue to deliver the value of AI to even more beneficiaries through a wide range of biosignal initiatives, including the use of ECG data with its significant potential for providing clues to serious heart-related diseases."
VUNO is the only Korean company to be triple-designated for Breakthrough Devices, with the VUNO Med®-Fundus AI(TM) selected as Korea's first Breakthrough Device and the VUNO Med®-DeepCARS(TM) receiving the sixth designation.
About VUNO Inc.
VUNO is a Seoul-based leading AI medical software company that applies deep learning to develop data-driven AI medical solutions using medical imaging, pathology, biosignal and medical speech data. We strive to present a whole new level of experience to medical practitioners in their day-to-day workflows, empowering them to make better diagnostic decisions faster and more accurately and to provide quality patient care and treatment planning to patients. For more information, visit www.vuno.co.
View original content to download multimedia:https://www.prnewswire.com/news-releases/vuno-med-deepecg-designated-as-breakthrough-device-301413938.html
SOURCE VUNO Inc.
|
|
|
|
|
 |
Asetek - Mandatory Notification of Trade | Jan 22, 2026
|
|
Tomorrowland Brings the Magic to Shanghai for a Spectacular First Indoor Edition in China | Jan 22, 2026
|
|
BC.GAME to Host "Stay Untamed" Night During Abu Dhabi's Packed Web3 Summit Week | Jan 22, 2026
|
|
Auburn University's Applied Research Institute Expands Advanced Manufacturing Capabilities with CF3D Enterprise Cell | Jan 22, 2026
|
|
Rent Manager Earned Best Real Estate Software Product Award and Multiple Review Badges from G2 Platform | Jan 22, 2026
|
|
California Divorce Mediation Center Unveils Modern Website Redesign | Jan 22, 2026
|
|
AMPERA ANNOUNCES LOCATION FOR GLOBAL HEADQUARTERS | Jan 22, 2026
|
|
Immutable Announces First Co-Founder-Hosted Live Webinar: How to Dominate Your Steam Launch | Jan 22, 2026
|
|
Culture and tourism sectors thrive in Xiamen | Jan 22, 2026
|
|
StackGen Named in Four Gartner® Hype Cycles(TM) for Platform Engineering, Infrastructure Strategy, Site Reliability Engineering, and I&O Automation in 2025 | Jan 22, 2026
|
|
|
